ReviewThe journal of allergy and clinical immunology. In practice2023
Who Needs Epinephrine? Anaphylaxis, Autoinjectors, and Parachutes.
Review in The journal of allergy and clinical immunology. In practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Risk of anaphylaxis on commercial flights.Current opinion in allergy and clinical immunology · 2025Pooled it
- Effect of Intramuscular Adrenaline on Histamine-Induced Hypotension: A Randomised Placebo-Controlled Pilot Trial.Allergy · 2026Trial
- Clinical Implications of Incidental Arg r 1 Sensitization Identified by Multiplex Allergy Testing.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
- Epinephrine Underuse for Anaphylaxis in Infants and Toddlers: A Practical Review for Pediatricians.Paediatric drugs · 2026Review
- Nationwide epinephrine auto-injector dispensing in Greece: a drug-utilization study providing insights into anaphylaxis epidemiology and emergency-treatment preparedness.Frontiers in allergy · 2026Article
- Global disparities in adrenaline access: A World Allergy Organization call for equity in anaphylaxis care.The World Allergy Organization journal · 2025Article
- Article
- Anaphylaxis definition, overview, and clinical support tool: 2024 consensus report-a GAThe Journal of allergy and clinical immunology · 2025Article
- Investigating health care pathways for anaphylaxis: Seeing the bigger picture through linked data.The journal of allergy and clinical immunology. Global · 2025Article
- Article
- Adrenaline Auto-Injectors for Preventing Fatal Anaphylaxis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- 10 practical priorities to prevent and manage serious allergic reactions: GAClinical and translational allergy · 2024Review
- To the ER? Can Patients Treat Their Anaphylaxis at Home?Current allergy and asthma reports · 2024Review
- Beta-Blockers as an Immunologic and Autonomic Manipulator in Critically Ill Patients: A Review of the Recent Literature.International journal of molecular sciences · 2024Review
- Epinephrine autoinjectors for individuals with food allergy: Who, how many, and when to use.Journal of food allergy · 2024Article
- Fatal food anaphylaxis in adults and children.Italian journal of pediatrics · 2024Review
- Refractory Anaphylaxis: A New Entity for Severe Anaphylaxis.The journal of allergy and clinical immunology. In practice · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
International guidelines stipulate that intramuscular (IM) epinephrine (adrenaline) is the first-line treatment for anaphylaxis, with an established good safety profile. The availability of epinephrine autoinjectors (EAI) has greatly facilitated the lay administration of IM epinephrine in community settings. However, key areas of uncertainty remain around epinephrine usage. These include variations in prescribing EAI, what symptoms should prompt epinephrine administration, whether emergency medical services (EMS) need to be contacted after administration, and whether epinephrine administered via EAI reduces mortality from anaphylaxis or improves quality of life measures. We provide a balanced commentary on these issues. There is increasing recognition that a poor response to epinephrine, particularly after 2 doses, is a useful marker of severity and the need for urgent escalation. It is likely that patients who respond to a single epinephrine dose do not require EMS activation or emergency department transfer, but data are needed to demonstrate the safety of this approach. Lastly, patients at risk of anaphylaxis must be counseled against over-reliance on EAI alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.